Alina S. Bandelyuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alina S. Bandelyuk has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Maxim Michaylovich Shmarov
National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, Ministry of Health of the Russian Federation, Moscow
10 shared publications - Alexander Gintsburg
National Research Center for Epidemiology and Microbiology Named after the Honorary Academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia
8 shared publications - Dmitrii N. Shcherbinin
Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
6 shared publications - Denis Yu. Logunov
Federal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named After Honorary Academician N. F. Gamaleya”, the Ministry of Health of the Russian Federation, Moscow 123098, Russia
5 shared publications - Lyudmila V. Verkhovskaya
National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, Ministry of Health of the Russian Federation, Moscow
5 shared publications - Olga V. Zubkova
N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology, Ministry of Health, Moscow 123098, Russia
5 shared publications
Latest Publications
- Open Access
- 21 March 2025
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 25 (1) , 7-21
Safety, reactogenicity, and immunogenicity of a viral vector vaccine against influenza A: Phase I open clinical trial
INTRODUCTION. The development of universal influenza vaccines based on conserved influenza virus antigens is a promising strategy for preventing pandemic influenza. Recombinant vaccines based on adenoviral vectors have high antiviral potential and have proven their effectiveness during the COVID-19 pandemic. In this regard, the development and clinical evaluation of a viral vector vaccine against influenza A seem relevant.AIM. The aim was to evaluate the safety, reactogenicity, and immunogenicity of a broad-spectrum viral vector vaccine against influenza A after a single intranasal administration in healthy volunteers.MATERIALS AND METHODS. This clinical trial studied the GamFluVac recombinant human adenovirus serotype 5 (rAd5)-based vaccine against influenza A (National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya). The clinical trial enrolled 36 volunteers. The follow-up period was 28 days. The safety assessment of the viral vector vaccine was based on the incidence, nature, and severity of adverse events (AEs) after a single intranasal administration at doses of 2.5×1010 (Group 1), 1.0×1011 (Group 2), and 2.5×1011 (Group 3) viral particles. Immunogenicity was evaluated by measuring serum IgG antibodies against influenza A (H5N2) by enzyme immunoassay on Day 0 and Day 28.RESULTS. No serious or severe AEs were reported during the clinical trial. Most AEs associated with the vaccine manifested as respiratory disorders, abnormal blood findings, and general disorders (elevated body temperature, headache, chills, malaise, arthralgia, and myalgia). Statistically significant differences (p=0.0285) were identified in the incidence of general disorders and administration site conditions in Group 1 (0%), Group 2 (16.7%), and Group 3 (33.3%). Group 3 demonstrated the highest increase in the geometric mean titres of specific IgG antibodies (2.8 times the baseline) on Day 28. In this group, 100% of volunteers had a ≥2-fold seroconversion rate, and 41.7% of volunteers had a ≥4-fold seroconversion rate.CONCLUSIONS. This phase I clinical trial of the GamFluVac viral vector vaccine against influenza A demonstrated the immunogenicity and favourable safety profile of the vaccine after a single intranasal administration.
- 21 March 2025
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 25 (1) , 7-21
Open AccessSafety, reactogenicity, and immunogenicity of a viral vector vaccine against influenza A: Phase I open clinical trial
INTRODUCTION. The development of universal influenza vaccines based on conserved influenza virus antigens is a promising strategy for preventing pandemic influenza. Recombinant vaccines based on adenoviral vectors have high antiviral potential and have proven their effectiveness during the COVID-19 pandemic. In this regard, the development and clinical evaluation of a viral vector vaccine against influenza A seem relevant.AIM. The aim was to evaluate the safety, reactogenicity, and immunogenicity of a broad-spectrum viral vector vaccine against influenza A after a single intranasal administration in healthy volunteers.MATERIALS AND METHODS. This clinical trial studied the GamFluVac recombinant human adenovirus serotype 5 (rAd5)-based vaccine against influenza A (National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya). The clinical trial enrolled 36 volunteers. The follow-up period was 28 days. The safety assessment of the viral vector vaccine was based on the incidence, nature, and severity of adverse events (AEs) after a single intranasal administration at doses of 2.5×1010 (Group 1), 1.0×1011 (Group 2), and 2.5×1011 (Group 3) viral particles. Immunogenicity was evaluated by measuring serum IgG antibodies against influenza A (H5N2) by enzyme immunoassay on Day 0 and Day 28.RESULTS. No serious or severe AEs were reported during the clinical trial. Most AEs associated with the vaccine manifested as respiratory disorders, abnormal blood findings, and general disorders (elevated body temperature, headache, chills, malaise, arthralgia, and myalgia). Statistically significant differences (p=0.0285) were identified in the incidence of general disorders and administration site conditions in Group 1 (0%), Group 2 (16.7%), and Group 3 (33.3%). Group 3 demonstrated the highest increase in the geometric mean titres of specific IgG antibodies (2.8 times the baseline) on Day 28. In this group, 100% of volunteers had a ≥2-fold seroconversion rate, and 41.7% of volunteers had a ≥4-fold seroconversion rate.CONCLUSIONS. This phase I clinical trial of the GamFluVac viral vector vaccine against influenza A demonstrated the immunogenicity and favourable safety profile of the vaccine after a single intranasal administration.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 46 (6)
Recombinant human adenovirus expressing a modified hemagglutinin induces cross-protection against heterologous influenza viruses A/H1N1
Рекомбинантный аденовирус человека, экспрессирующий модифицированный ген гемагглютинина, индуцирует перекрестную защиту от гетерологичных вирусов
- 1 January 2025
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 46 (6)
Open AccessRecombinant human adenovirus expressing a modified hemagglutinin induces cross-protection against heterologous influenza viruses A/H1N1
Рекомбинантный аденовирус человека, экспрессирующий модифицированный ген гемагглютинина, индуцирует перекрестную защиту от гетерологичных вирусов
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 46 (5)
mRNA as a perspective prime-component for universal influenza A vaccine
мРНК как перспективный прайм-компонент универсальной вакцины против гриппа А
- 1 January 2025
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 46 (5)
Open AccessmRNA as a perspective prime-component for universal influenza A vaccine
мРНК как перспективный прайм-компонент универсальной вакцины против гриппа А
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (5)
Comparison of the transduction efficiency of human dendritic cells using adenoviral vectors of different serotypes
Сравнение эффективности трансдукции дендритных клеток человека с помощью аденовирусных векторов различных серотипов
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (5)
Open AccessComparison of the transduction efficiency of human dendritic cells using adenoviral vectors of different serotypes
Сравнение эффективности трансдукции дендритных клеток человека с помощью аденовирусных векторов различных серотипов
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (5)
Vector-neutralizing activity of serum antibodies during revaccination with adenovirus vaccine «Sputnik Light»
Вектор-нейтрализующая активность сывороточных антител при ревакцинации аденовирусной вакциной
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (5)
Open AccessVector-neutralizing activity of serum antibodies during revaccination with adenovirus vaccine «Sputnik Light»
Вектор-нейтрализующая активность сывороточных антител при ревакцинации аденовирусной вакциной
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (4)
Transduction of human B lymphocytes using adenoviral vectors of various serotypes
Трансдукция В-лимфоцитов человека с помощью аденовирусных векторов различных серотипов
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (4)
Open AccessTransduction of human B lymphocytes using adenoviral vectors of various serotypes
Трансдукция В-лимфоцитов человека с помощью аденовирусных векторов различных серотипов
- Open Access
- 20 March 2023
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 18 (1) , 48–64
Method for obtaining recombinant antibodies produced by a cell line transduced with recombinant adenoviruses
Objectives. To develop a technology for obtaining recombinant antibodies in a suspension culture of human HEK293 cells using transduction with recombinant adenovirus serotype 5 (rAd5) carrying genes expressing heavy and light chains of antibodies on the example of two broadspectrum anti-influenza antibodies 27F3 and CR9114.Methods. Ad5-27F3-H, Ad5-CR9114-H, and Ad5-27F3-L recombinant adenoviruses carrying the 27F3 antibody heavy chain gene, CR9114 antibody heavy chain gene, and 27F3 light chain gene, respectively, were generated using the AdEasy™ Adenoviral vector system. To accumulate preparative amounts of recombinant r27F3 and rCR9114 antibodies, the HEK293 suspension cell line was transduced with recombinant adenoviruses carrying genes for heavy and light chains of antibodies. The cells were cultured in a wave-type bioreactor. Chromatography was used to purify recombinant antibodies from the culture medium. After analyzing the molecular weights of purified antibodies using protein electrophoresis, their ability to interact with influenza A and B viruses was analyzed using the Western blot technique, while their ability to neutralize influenza A and B viruses was evaluated using the virus neutralization assay.Results. A method for the accumulation and purification of recombinant r27F3 and CR9114 antibodies from the culture medium of a suspension culture of human cells following transduction with its recombinant adenoviruses carrying the genes for heavy and light chains of these antibodies was developed. The ability of the r27F3 antibody to interact with and neutralize influenza A viruses of group 1 (except influenza A virus subtype H2) and group 2 was shown. The ability of the rCR9114 antibody to interact with influenza A viruses of group 1 and influenza B viruses, as well as to neutralize influenza A viruses of group 1, was demonstrated.Conclusions. A technology for obtaining recombinant antibodies in a suspension culture of HEK293 cells using transduction with recombinant adenoviruses carrying genes expressing heavy and light chains of antibodies was developed along with a confirmation of their specificity.
- 20 March 2023
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 18 (1) , 48–64
Open AccessMethod for obtaining recombinant antibodies produced by a cell line transduced with recombinant adenoviruses
Objectives. To develop a technology for obtaining recombinant antibodies in a suspension culture of human HEK293 cells using transduction with recombinant adenovirus serotype 5 (rAd5) carrying genes expressing heavy and light chains of antibodies on the example of two broadspectrum anti-influenza antibodies 27F3 and CR9114.Methods. Ad5-27F3-H, Ad5-CR9114-H, and Ad5-27F3-L recombinant adenoviruses carrying the 27F3 antibody heavy chain gene, CR9114 antibody heavy chain gene, and 27F3 light chain gene, respectively, were generated using the AdEasy™ Adenoviral vector system. To accumulate preparative amounts of recombinant r27F3 and rCR9114 antibodies, the HEK293 suspension cell line was transduced with recombinant adenoviruses carrying genes for heavy and light chains of antibodies. The cells were cultured in a wave-type bioreactor. Chromatography was used to purify recombinant antibodies from the culture medium. After analyzing the molecular weights of purified antibodies using protein electrophoresis, their ability to interact with influenza A and B viruses was analyzed using the Western blot technique, while their ability to neutralize influenza A and B viruses was evaluated using the virus neutralization assay.Results. A method for the accumulation and purification of recombinant r27F3 and CR9114 antibodies from the culture medium of a suspension culture of human cells following transduction with its recombinant adenoviruses carrying the genes for heavy and light chains of these antibodies was developed. The ability of the r27F3 antibody to interact with and neutralize influenza A viruses of group 1 (except influenza A virus subtype H2) and group 2 was shown. The ability of the rCR9114 antibody to interact with influenza A viruses of group 1 and influenza B viruses, as well as to neutralize influenza A viruses of group 1, was demonstrated.Conclusions. A technology for obtaining recombinant antibodies in a suspension culture of HEK293 cells using transduction with recombinant adenoviruses carrying genes expressing heavy and light chains of antibodies was developed along with a confirmation of their specificity.
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (5)
Study of the antigenic specificity of T-cell immune reactions in response to immunization of laboratory mice with a recombinant adenoviral vector encoding the Spike-protein of SARS-CoV-2
Исследование антигенной специфичности Т-клеточных иммунных реакций в ответ на иммунизацию лабораторных мышей рекомбинантным аденовирусным вектором,
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (5)
Open AccessStudy of the antigenic specificity of T-cell immune reactions in response to immunization of laboratory mice with a recombinant adenoviral vector encoding the Spike-protein of SARS-CoV-2
Исследование антигенной специфичности Т-клеточных иммунных реакций в ответ на иммунизацию лабораторных мышей рекомбинантным аденовирусным вектором,